Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Daiichi Sankyo Inks ADC License Pact with Glycotope
Daiichi Sankyo said on July 30 that it has sealed a licensing agreement with Berlin-based Glycotope to develop an antibody drug conjugate (ADC) by applying its ADC technologies to the German partner’s investigational tumor-associated TA-MUC1 antibody gatipotuzumab. The deal is…
To read the full story
Related Article
- Daiichi Sankyo Unveils Dose-Escalation Data on TA-MUC1-Targeting ADC
October 22, 2025
- Daiichi Buys IP Rights to Glycotope’s TA-MUC1 Antibody
January 15, 2025
- Daiichi Sankyo Pairs Up with German Startup to Develop ADC for Solid Cancer
November 1, 2017
BUSINESS
- Toho Builds Alternative Drug Delivery Options for Disaster Readiness
August 25, 2026
- OB/GYN Sees Abrysvo Becoming Part of Prenatal Care as NIP Drives Uptake
August 25, 2026
- Daiichi Sankyo Taps Ken Keller as New Commercial Chief in Global Revamp
August 25, 2026
- MSD Launches RSV Antibody Enflonsia in Japan without NHI Listing
August 24, 2026
- Sumitomo Pharma Eyes Global Position as Adjuvant Supplier
August 24, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…